Xencor reported $25.1M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Cytokinetics USD -160.3M 9.02M Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
J&J USD 8.99B 721M Jun/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -64.54M 34.34M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Novartis USD 8.62B 2.14B Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Xencor USD 25.1M 59.73M Sep/2026